On the 19th of October 2022, Brain+ A/S (“Brain+” or the ”Company”) announced that the Company has been selected and featured as a 2022 TMC-Denmark Biobridge Partner in the new Texas Medical Center (TMC) new 2022 Biobridge e-book, hence building early traction within the US market.
Back in 2019, TMC – the world’s largest medical city – and the Danish Ministry of Health entered a collaboration and multi-faceted global life science Biobridge partnership to advance commercial and clinical innovation, to enable research collaborations and knowledge transfer. The Biobridge intends to serve as a marketplace for innovative life science technologies focused on digital & telehealth, medical devices, and operations.
By being a part of the TMC-Denmark Biobridge Partnership, Brain+ gains not only increased brand awareness at TMC and the US market as a whole, but also get access to valuable know-how and go-to-market research that opens up doors to explorative dialogues with American market participants within the healthcare space. Increased brand awareness within the US is of great importance for Brain+ in terms of future strategic partnerships and with the number of +USD 100m licensing/partnership deals that have been made during recent years, it is clear that life science participants are on the outlook for new partners, creating an opportunity for Brain+ going forward.
The US is the biggest healthcare market in the world and more than seven million people in the ages 65 or older had dementia in 2020. The price/reimbursement levels are also significantly higher than the rest of the world, roughly three times higher than in Europe, where prices could be beyond EUR 1,000 per treatment. Thus, the US market is highly attractive, and while Analyst Group has not explicitly modeled any revenues in the US within our forecast period, as the commercialization phase is estimated to be several years away, we consider the recent early signs of progress in the US as highly positive.
Read our latest equity report of Brain+ here.
